References
- Seeger TF, Seymour PA, Schmidt AW, Zorn SH, Schulz DW, Lebel LA, et al. Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity. J Pharmacol Exp Ther 1995; 275(1): 101–13.
- Schmidt AW, Lebel LA, Howard HR Jr, Zorn SH. Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile. Eur J Pharmacol 2001; 425(3): 197–201.
- Caley CF, Cooper CK. Ziprasidone: the fifth atypical antipsychotic. Ann Pharmacother 2002; 36(5): 839–51.
- Greenberg WM, Citrome L. Ziprasidone for schizophrenia and bipolar disorder: a review of the clinical trials. CNS Drug Rev 2007; 13(2): 137–77.
- Mathews M, Muzina DJ. Atypical antipsychotics: new drugs, new challenges. Cleve Clin J Med 2007; 74(8): 597–606.
- Agarwal PA, Ichaporia NR. Flupenthixol-induced tardive dystonia presenting as severe dysphagia. Neurol India 2010; 58(5): 784–5.
- Aggarwal A, Jiloha RC. Olanzapine induced tardive dystonia. Indian J Pharmacol 2008; 40(5): 237–8.
- Duggal HS, Mendhekar DN. Clozapine-induced tardive dystonia (blepharospasm). J Neuropsychiatry Clin Neurosci 2007; 19(1): 86–7.
- Peacock L, Solgaard T, Lublin H, Gerlach J. Clozapine versus typical antipsychotics. A retro- and prospective study of extrapyramidal side effects. Psychopharmacology (Berl) 1996; 124(1–2): 188–96.
- Stahl SM, Davis KL, Berger PA. The neuropharmacology of tardive dyskinesia, spontaneous dyskinesia, and other dystonias. J Clin Psychopharmacol 1982; 2(5): 321–8.
- Papapetropoulos S, Wheeler S, Singer C. Tardive dystonia associated with ziprasidone. Am J Psychiatry 2005; 162(11): 2191.
- Tibrewal P, Zutshi A, Math SB. Tardive dystonia and ziprasidone: a case report. Prim Care Companion J Clin Psychiatry 2008; 10(1): 71–2.
- Tsai CS, Lee Y, Chang YY, Lin PY. Ziprasidone-induced tardive laryngeal dystonia: a case report. Gen Hosp Psychiatry 2008; 30(3): 277–9.
- Kutlu A, Dündar S, Altun NS, Budak F. Ziprasidone induced tardive cervical dystonia. Psychopharmacology Bulletin 2009 42(4): 64–8.
- Raja M. Managing antipsychotic-induced acute and tardive dystonia. Drug Saf 1998; 19(1): 57–72.
- Brans JW, Lindeboom R, Snoek JW. Botulinum toxin versus trihexyphenidyl in cervical dystonia: a prospective, randomized, double-blind controlled trial. Neurology 1996; 46 (4): 1066–72.
- Jankovic J. Botulinum toxin in clinical practice. J Neurol Neurosurg Psychiatry 2004; 75(7): 951–7.
- Lencer R, Eismann G, Kasten M, Kabakci K, Geithe V, Grimm J, et al. Family history of primary movement disorders as a predictor for neuroleptic-induced extrapyramidal symptoms. Br J Psychiatry 2004 185: 465–71.
- Habermeyer B, Rabovsky K, Jentzsch C, Pinhard K, MüllerSpahn F. Cervical dystonia due to interaction of valproic acid and quetiapine. J Clin Psychopharmacol 2007; 27(4): 396–7.
- Yohanan M, Aulakh JS, Weith J, Hawkins JW. Pisa syndrome in a patient in a wheelchair taking valproic acid. Am J Psychiatry 2006; 163(2): 325–6.
- Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimting the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30(2): 239–45.